1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. California >
  6. Abcam Acquires BioVision

M&A Deal Summary

Abcam Acquires BioVision

On August 2, 2021, Abcam acquired life science company BioVision for 340M USD

Acquisition Highlights
  • This is Abcam’s 8th transaction in the Life Science sector.
  • This is Abcam’s largest (disclosed) transaction.
  • This is Abcam’s 7th transaction in the United States.
  • This is Abcam’s 4th transaction in California.

M&A Deal Summary
Date 2021-08-02
Target BioVision
Sector Life Science
Buyer(s) Abcam
Deal Type Add-on Acquisition
Deal Value 340M USD

Target

BioVision

Milpitas, California, United States
BioVision is a privately-held life science company that develops and offers a wide variety of products including assay kits, antibodies, recombinant proteins & enzymes, and other innovative research tools for studying Apoptosis, Metabolism, Cell Proliferation, Cellular Stress, Cell Damage and Repair, Diabetes, Obesity and Metabolic Syndrome, Stem Cell Biology, Gene Regulation, Signal Transduction, etc. BioVision was formed in 1999 and is based in Milpitas, California.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Abcam

Cambridge, United Kingdom
Category Company
Founded 1998
Sector Life Science
Employees1,682
Revenue 362M GBP (2022)
DESCRIPTION

Abcam is a producer and marketer of high quality protein research tools. These tools enable life scientists to analyze components of living cells at the molecular level which is essential in a wide range of fields including drug discovery, diagnostics, and basic research. Abcam was founded in 1998 and is based in Cambridge, the United Kingdom.

DEAL STATS #
Overall 8 of 8
Sector: Life Science M&A 8 of 8
Type: Add-on Acquisition M&A Deals 7 of 7
State: California M&A 4 of 4
Country: United States M&A 7 of 7
Year: 2021 M&A 1 of 1
Size (of disclosed) 1 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-01-30 Applied StemCell - Gene Editing Platform & Oncology Product Portfolio

Milpitas, California, United States

Applied StemCell's Gene Editing Platform & Oncology Product Portfolio focused on developing genome editing technologies into novel therapeutics to advance drug discovery.

Buy -
Mergr

Solution for

Product

Company

Legal